anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To acquire cell images to use for pathologic diagnosis without removing Sentinel Lymph Node where a tumor metastasizes first in case of spreading to a lymph node by metastasis. SOLUTION: Gamma ray is emitted from radioisotope injected around a tumor in advance, and Sentinel Lymph Node 1 is detected by measuring amount of gamma ray with a gamma probe 80. Low coherence light L1 with 1.4 μm of coherence length projected from a light source 100 of Optical Coherence Tomography 11 is divided into a signal beam L4 and a reference beam L3 by a fiber combination optical system 120. The signal beam L2 is irradiated to detected Sentinel Lymph Node 1, and the frequency of the reference beam L3 is shifted to a frequency slightly different from that of the signal beam L4. A light when the signal beam L4 reflects at a predetermined depth of the Sentinel Lymph Node 1 is interfered with the reference beam L3.  Intensity of the interference light is measured at a balance detecting part 150, and cell images of the Sentinel Lymph Node of ultra-high resolution optical tomographic images are acquired.
Dimefluthrin (DIM) is a commonly utilized sanitary insecticide, predominantly employed for indoor pest management within residential and public environments directly interacting with human habitation. However, the usage of DIM is escalating with increasing mosquito resistance, prompting concerns about its health risks. Here, using zebrafish as a research model, we systematically evaluated DIM's impact on human health. Findings revealed significant health hazards during embryonic development, including reduced hatching rates, shortened body lengths, and organ malformations, notably affecting the heart. It was explored the mechanism of DIM-induced cardiotoxicity in zebrafish, and histopathological analyses revealed that DIM resulted in ventricular linearization in zebrafish embryos. Antioxidant enzyme activities were reduced and cardiac reactive oxygen species (ROS) accumulated after DIM exposure, suggesting clear signs of oxidative stress. Additionally, acridine orange (AO) staining and caspase-3 immunofluorescence demonstrated cardiac apoptosis in Tg (kdrl: EGFP) zebrafish. qPCR analysis implied that DIM induced apoptosis via the p53/Caspase pathway by up-regulating the expression levels of p53, cytochrome C (cyto-C), caspase-9, and caspase-3. Together, our work provided a systematic perspective on the cardiotoxicity of sanitary pesticides, which could offer opportunities for future risk management.
Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropine-like signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

The treatment of overdosage consists of discontinuation of Karbinal ER and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.
Risk Summary

There are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. In animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the MRHD for Parkinson’s disease. Ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. In pregnant rabbits, ropinirole potentiated the teratogenic effects of L-dopa when these drugs were administered in combination [see Data]. 

In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage in the indicated populations is unknown.

Data

Animal Data: Oral administration of ropinirole (0, 20, 60, 90, 120, or 150 mg/kg/day) to pregnant rats during organogenesis resulted in embryolethality, increased incidence of fetal malformations (digit, cardiovascular, and neural tube defects) and variations, and decreased fetal weight at the 2 highest doses. These doses were also associated with maternal toxicity. The highest no-effect dose for adverse effects on embryofetal development (90 mg/kg/day) is approximately 36 times the MRHD for Parkinson’s disease (24 mg/day) on a body surface area (mg/m2) basis. 

No effect on embryofetal development was observed in rabbits when ropinirole was administered alone during organogenesis at oral doses of 0, 1, 5, or 20 mg/kg/day (up to 16 times the MRHD on a mg/m2 basis). In pregnant rabbits, there was a greater incidence and severity of fetal malformations (primarily digit defects) when ropinirole (10 mg/kg/day) was administered orally during gestation in combination with L-dopa (250 mg/kg/day) than when L-dopa was administered alone. This drug combination was also associated with maternal toxicity. 

Oral administration of ropinirole (0, 0.1, 1, or 10 mg/kg/day) to rats during late gestation and continuing throughout lactation resulted in neurobehavioral impairment (decreased startle response) and decreased body weight in offspring at the highest dose. The no-effect dose of 1 mg/kg/day is less than the MRHD on a mg/m2 basis.
Tumor angiogenesis, the formation of new blood vessels to support tumor growth and metastasis, is a complex process regulated by a multitude of signaling pathways. Dysregulation of signaling pathways involving protein kinases has been extensively studied, but the role of protein phosphatases in angiogenesis within the tumor microenvironment remains less explored. However, among angiogenic pathways, protein phosphatases play critical roles in modulating signaling cascades. This review provides a comprehensive overview of the involvement of protein phosphatases in tumor angiogenesis, highlighting their diverse functions and mechanisms of action. Protein phosphatases are key regulators of cellular signaling pathways by catalyzing the dephosphorylation of proteins, thereby modulating their activity and function. This review aims to assess the activity of the protein tyrosine phosphatases and serine/threonine phosphatases. These phosphatases exert their effects on angiogenic signaling pathways through various mechanisms, including direct dephosphorylation of angiogenic receptors and downstream signaling molecules. Moreover, protein phosphatases also crosstalk with other signaling pathways involved in angiogenesis, further emphasizing their significance in regulating tumor vascularization, including endothelial cell survival, sprouting, and vessel maturation. In conclusion, this review underscores the pivotal role of protein phosphatases in tumor angiogenesis and accentuate their potential as therapeutic targets for anti-angiogenic therapy in cancer.
PURPOSE: Microfibers for drug delivery are provided to deliver various drugs at a time and easily control a complex mechanism such as an output rate or total dosage time through the correction of hydro gel materials. CONSTITUTION: Microfibers for drug delivery include two or more sections in which porosity is different in a longitudinal direction and at least one section among the two or more sections contains drugs. The microfibers for drug delivery include a high porous first section, a middle porous second section and a low porous third section in the longitudinal direction. The first section includes drugs for fast release. The second section includes drugs for middle release. The third section includes drugs for slow release.
Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
Depression and cognitive impairment are prevalent conditions among people with HIV (PWH), likely attributable to shared causes and common risk factors. Identifying subtypes of PWH with similar patterns of neurocognitive impairment (NCI) and depressive symptoms may inform development of patient-centered interventions that target-specific profiles. This study aimed to (1) classify PWH based on patterns of domain-specific NCI and depression; and (2) determine the relationship between latent class membership and pertinent clinical characteristics. PWH (N = 580, 86.2% male, 57.1% non-Hispanic White, 69.2% unemployed) completed a comprehensive neuropsychological test battery assessing global and domain-specific cognition. Domain-specific NCI was classified as deficit score >0.5. Participants completed the Beck Depression Inventory-II (BDI-II), and domain-specific BDI-II scores reflecting cognitive, affective, and somatic symptoms were computed. Latent profile analysis (LPA) was used to determine latent subgroups of NCI and depression. The optimal LPA solution consisted of five classes: minimal NCI and minimal depression (Class 1), amnestic and minimal depression (Class 2), severe multi-domain NCI and moderate depression (somatic and affective; Class 3), mild NCI and mild depression (Class 4), and moderate multi-domain NCI and severe depression (Class 5). Despite similar levels of functional impairment, Class 5 had a significant psychiatric profile, whereas Class 3 had a complex medical profile (i.e., higher frailty index, higher medications, greater proportion of AIDS diagnosis). In contrast, Class 1 had the lowest medication use and frailty index, with similar HIV disease characteristics to Classes 3 and 5. Our results suggest there are multiple pathways to cognitive and functional impairment among PWH with co-occurring depression and cognitive impairment, and these groups may respond differently to interventions. Of note, our sample was majority non-Hispanic White and male, which is nonrepresentative of the US population of PWH. Future interventions should consider a more integrated, person-centered approach that addresses cognitive and emotional health to optimize health outcomes in PWH.
PROBLEM TO BE SOLVED: To provide compositions and methods for preparing concentrated stock solutions of AAV virions without aggregation.SOLUTION: Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ-500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x10vg/mL are possible using the formulations, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic(R) F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
<P>PROBLEM TO BE SOLVED: To support effective primary analysis on the cause of variance by properly presenting a phenomenon having strong possibility of the cause of the variance even if there are a small number of cases of the same variance so as to effectively improve a clinical path.  <P>SOLUTION: A causal relationship candidate is generated by a cause candidate dictionary construction means 106, and is accumulated in a cause candidate dictionary database 105. When the analysis target variance is selected through an input means 109, execution recording data of a patient wherein the analysis target variance occurs are first acquired from an electronic medical chart system through an electronic medical chart cooperation means 103. Next, in a variance cause candidate extraction means 104, the execution recording data of the patient wherein the analysis target variance occurs and the causal relationship candidate are compared, and the causal relationship candidate according to the execution recording data and having high use frequency is presented on a display means 108 as a cause candidate wherein the variance of an analysis target case occurs. Thereby, a variance cause system is materialized.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
Participants will take a daily oral combination of 2 NRTIs plus DTG 50mg. Ideally, the single tablet fixed-dose combination regimen of (tenofovir disoproxil fumarate \[TDF\] 300 mg + lamivudine \[3TC\] 300 mg (or emtricitabine \[FTC\] 200 mg) + DTG 50 mg) will be used as per local country guidelines up to Month 24. If there are preexisting reasons why TDF or 3TC cannot be used as the NRTI backbone then alternative NRTIs are acceptable. Participants will be permitted to switch daily oral ART drugs in case of toxicity, after discussion with the coordinating center.
Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (CpG) sites, have been linked to kidney function and may have clinical utility in predicting the risk of CKD. Given the dynamic relationship between the epigenome, environment, and disease, AAs may be especially sensitive to environment-driven methylation alterations. Moreover, risk models incorporating CpG methylation have been shown to predict disease across multiple racial groups. In this study, we developed a methylation risk score (MRS) for CKD in cohorts of AAs. We selected nine CpG sites that were previously reported to be associated with estimated glomerular filtration rate (eGFR) in epigenome-wide association studies to construct a MRS in the Hypertension Genetic Epidemiology Network (HyperGEN). In logistic mixed models, the MRS was significantly associated with prevalent CKD and was robust to multiple sensitivity analyses, including CKD risk factors. There was modest replication in validation cohorts. In summary, we demonstrated that an eGFR-based CpG score is an independent predictor of prevalent CKD, suggesting that MRS should be further investigated for clinical utility in evaluating CKD risk and progression.
Measurable residual disease (MRD) evaluation by multiparameter flow cytometry (MFC) or quantitative polymerase chain reaction methods is an established standard of care for assessing risk of relapse before or after hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL). Next-generation sequencing (NGS)-MRD has emerged as a highly effective approach that allows for the detection of lymphoblasts at a level of <1 in 106 nucleated cells, increasing sensitivity of ALL detection by 2 to 3 logs. Early studies have shown superior results compared with MFC and suggest that NGS-MRD may allow for the determination of patients in whom reduced toxicity transplant preparative approaches could be deployed without sacrificing outcomes. Many centers/study groups have implemented immune modulation approaches based on MRD measurements that have resulted in improved outcomes. Challenges remain with NGS-MRD, because it is not commercially available in many countries, and interpretation of results can be complex. Through patient case review, discussion of relevant studies, and detailed expert opinion, we share our approach to NGS-MRD testing before and after HCT in pediatric and adult ALL. Improved pre-HCT risk classification and post-HCT monitoring for relapse in bone marrow and less invasive peripheral blood monitoring by NGS-MRD may lead to alternative approaches to prevent relapse in patients undergoing this challenging procedure.
Patients will be advised to discontinue any other products, other than a mild cleanser, prior to beginning treatment. Patients will engage in a split face trial, where each participant uses the vehicle on one side of the face and active ingredient treatment cream on the other side. Baseline facial photography and OCT imaging will be performed on both sides of the face. One side of the face will be randomly chosen as the treatment side, and the other as an intrinsic control. Each day, the participant will wash their face in the morning with a standard cleanser, dry their face, then apply the medication to one side of their face and the vehicle to the other side of their face. The patient will then apply a standardized sunscreen SPF 30 to the entire face. Each night, the patient will again wash their face with the standard cleanser, and apply the two medications to the proper sides of the face. Patients will participate in a follow-up clinic visit 4 weeks, 8 weeks, 12 weeks and 16 weeks after beginning treatment. At each visit, photographs and OCT images will be taken of both sides of the face. At week 12, participants will take a survey to determine their satisfaction with the product and their subjective assessment of their skin changes and stop using the products and continue only the sunscreen. Four weeks after cessation of using the creams, they will return for photography and OCT imaging at a final visit.
PROBLEM TO BE SOLVED: To prepare an antiaging agent, capable of enhancing the productivity of hyaluronic acid with skin and preventing the skin from aging and suitable for a makeup cosmetic, a cosmetic for hair of the head, bathing agent, etc., including a basic cosmetic by blending an extract from a specific plant therein. SOLUTION: This antiaging agent comprises an extract from a plant belonging to the genus Tinospora of the family Menispermaceae, especially the one from Brotowali (botanical name: Tinospora tuberculata Beumee) which is a plant growing especially in a dry grassland, a pasture, etc., of Indonesia as an active ingredient. The amount of the blended extract is 0.0005-20.0wt.%, preferably 0.001-10.0wt.% expressed in terms of a dry substance in the total amount of a preparation for external use for skin. The antiaging agent is capable of preventing the skin from aging and maintaining a state of the youthful and healthy skin. The antiaging agent can widely be applied to a cosmetic, e.g. a basic cosmetic.
According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous (mesoporous) silica particles, in which one or more immunomodulatory imide drug is loaded into the pores of said particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter (MMAD) that is between about 0.95 µm and about 6.05 µm; and (b) a geometric standard deviation (GSD) that is no more than 1.33. The compositions are useful in the treatment of interstitial lung diseases by pulmonary administration. Preferred immunomodulatory imide drugs include thalidomide. Interstitial lung diseases that may be mentioned include idiopathic pulmonary fibrosis and sarcoidosis. The compositions comprise particles that are very small, but have a well-defined particle size distribution, with a low amount of fines. This has been surprisingly found to give rise to an unexpected lack of aggregation and unexpectedly good flow properties.
BACKGROUND: Hepatic stellate cells (HSCs) serve as the crucial accelerating factor in the progression of liver fibrosis (LF). In contrast to HSCs, adult-derived human liver stem/progenitor cells (ADHLSCs) exhibit greater potency in terms of differentiation and proliferation, rendering them highly applicable in LF treatment. The objective of this study is to identify new therapeutic targets for LF by comparing differentially expressed genes (DEGs) between ADHLSCs and HSCs.
METHODS: We investigated DEGs between ADHLSCs and HSCs using the GSE49995 dataset obtained from the Gene Expression Omnibus (GEO) database, aiming to identify new therapeutic targets for LF. Subsequently, we activated HSCs to delve deeper into the mesenchyme homeobox 2 (MEOX2), PH domain Leucine-rich repeat protein phosphatase (PHLPP), and Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways in LF progression, employing platelet-derived growth factor (PDGF), and conducted infection with Overexpression (OE)-MEOX2 and shRNA-MEOX2 (sh-MEOX2) lentiviruses. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, while cell proliferation was evaluated through 5-ethynyl-2'-deoxyuridine (EdU) staining and flow cytometry. Relative mRNA expression levels were determined via qPCR. Western blot analysis was performed to measure protein expression levels, and the regulatory role of MEOX2 was investigated using dual luciferase reporter assays.
RESULTS: We identified 332 DEGs that were down-regulated and 201 DEGs that were up-regulated between ADHLSCs and HSCs. Notably, MEOX2 expression in ADHLSCs was significantly reduced. These DEGs primarily participated in the collagen-containing extracellular matrix and the PI3K/AKT signaling pathway. MEOX2 could inhibit cancer cell proliferation via the PI3K/AKT signaling pathway. Additionally, the JASRPAR2022 database predicted the target gene PHLPP of MEOX2. Our results indicated that OE-MEOX2 significantly inhibited HSCs' cell vitality and proliferation. Further analysis revealed that MEOX2 binds to PHLPP promoters, thereby up-regulating its transcription. This action led to the inhibition of p-AKT expression, consequently reducing HSC proliferation and slowing the progression of LF.
CONCLUSIONS: MEOX2 up-regulates PHLPP expression and inhibits AKT phosphorylation, thereby reducing the cell activity and proliferation ability of HSCs and inhibiting the progression of LF.
The invention discloses application of GGPP (GGPP) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs. The amino acid sequence of the human FBP1 protein is shown as SEQID No. 1. The invention establishes a direct binding protein action network of GGPP in normal liver, and screens and verifies a plurality of GGPP binding proteins participating in regulation and control of hepatic glycolipid metabolism. The GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis, and can inhibit the migration of liver parenchymal cells and liver cancer cells. The GGPP is coupled with glycolipid metabolic balance through sensitizing a target protein FBP1 of the GGPP, so that a molecular mechanism for generation and development of hepatocellular carcinoma is regulated, and the GGPP can be applied to treatment of the hepatocellular carcinoma. GGPP regulates the metabolic balance of hepatic glycolipids by specifically and directly combining with a target protein FBP1, and provides a new potential target, a medicine and a treatment method for treating HCC.
A new use is claimed for hydroxycinnamic acid esters of formula (I) (where R1 is H or 1-4C alkyl; R2 is 1- 8C alkyl phenyl, benzyl or cyclohexyl; n is 1, 2 or 3), as antiinflammatory agents in cosmetics. Partic. useful in sunscreen compsns. associated with convention UV screening agents. The cpds. themselves absorb at 300 nm and also act as sunscreen agents. A typical sunscreen oil contained 20 g of ethyl 2-hydroxy-cinnamate and 30 g of menthyl salicylate in a mixt. of 300 g of vegetable oil contg. lecithin, 400 g of olive oil, 100g of isopropyl myristate and 100 g of oil from the fox uropygial gland.